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Background: National organizations recommend screening for hepatitis B virus (HBV) before chemotherapy but
differ regarding which patients should be screened. We aimed to determine contemporary screening rates at a
cancer center and the possible influence on these rates of publication of national recommendations.
Methods: We conducted a retrospective cohort study of HBV screening in cancer patients registered during the
period from January 2004 through April 2011. Screening was defined as HBsAg and anti-HBc tests ordered around the
time of initial chemotherapy. We compared screening rates for 3 periods: January 1, 2004, through December 18, 2008
(Food and Drug Administration and American Association for the Study of Liver Diseases 2007 recommendations);
December 19, 2008, through September 30, 2010 (Centers for Disease Control and Prevention, National Comprehensive
Cancer Network, American Association for the Study of Liver Diseases 2009, Institute of Medicine, and American Society
of Clinical Oncology recommendations); and October 1, 2010, through April 30, 2011. Logistic regression models were
used to identify predictors of screening.
Results: Of 141,877 new patients, 18,688 received chemotherapy, and 3020 (16.2%) were screened. HBV screening rates
increased over the 3 time periods (14.8%, 18.2%, 19.9%; P < 0.0001), but <19% of patients with HBV risk factors were
screened. Among patients with hematologic malignancies, over 66% were screened, and odds of screening nearly
doubled after publication of the recommendations (P < 0.0001). Less than 4% of patients with solid tumors were
screened, although odds of screening increased 70% after publication of the recommendations (P = 0.003). Other
predictors of screening included younger age, planned rituximab therapy, and known risk factors for
HBV infection.
Conclusions: Most patients with solid tumors or HBV risk factors remained unscreened, although screening
rates increased after publication of national recommendations. Efforts are needed to increase awareness of the
importance of HBV screening before chemotherapy to identify patients who should start antiviral prophylaxis.
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National [1-7] and international [8,9] recommendations for
hepatitis B virus (HBV) screening before chemotherapy
emphasize the need to identify patients with HBV infection
so that antiviral prophylaxis can be initiated to prevent re-
activation of HBV infection. The pooled (range) incidence
of HBV reactivation, HBV-related hepatitis, HBV-related
liver failure, and HBV-related death among cancer patients
receiving chemotherapy, who had not received antiviral* Correspondence: jphwang@mdanderson.org
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reproduction in any medium, provided the orprophylaxis has been reported to be 37% (24-88%), 33%
(24-88%), 13% (5-33%) and 7% (0-63%), respectively [10].
The 7 national recommendations, however, differ regarding
which patients should be screened [1-7] (Table 1). Unfortu-
nately, no population-based studies have been conducted
in the US to inform an evidence-based HBV screening
policy.
Although the rates of HBV screening before immuno-
suppressive therapy in the US are unknown because of
the lack of large-scale studies, rates have been estimated
through physician surveys, which have shown rates ran-
ging from 38-80% [11-13]. However, these studies were
limited by the potential for recall bias and low surveyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






1FDA Dear Healthcare Professional Letter 7/12/2004 Online only Screen patients at high risk of HBV infection before initiation
of rituximab therapy. Closely monitor carriers of HBV for
clinical and laboratory signs of active HBV infection and for
signs of hepatitis during and for up to several months after
rituximab therapy.
2AASLD 1/26/2007 2/2007 Screen patients at high risk for HBV infection prior to
immunosuppressive therapy.
Test with HBsAg.
3CDC 9/19/2008 9/19/2008 Screen all patients prior to immunosuppressive therapies.
Test with HBsAg, anti-HBc, and anti-HBs.
4AASLD Update 7/28/2009 9/2009 Screen patients at high risk for HBV infection prior to
immunosuppressive therapy.
Test with HBsAg and anti-HBc.
5NCCN 8/28/2009 Online only Screen cancer patients with lymphoid malignancies,
patients who have spent significant time in HBV-endemic
areas or have risk factors for HBV infection, and patients
anticipating intensive immunosuppressive therapy.
Test with HBsAg, anti-HBc, and anti-HBs.
6IOM 1/11/2010 1/11/2010 Screen patients with HBV risk factors.
Test with HBsAg.
7ASCO 6/1/2010 7/1/2010 Screen cancer patients at high risk for HBV infection or
anticipating highly immunosuppressive therapy such
as stem cell transplantation or rituximab therapy.
Test with HBsAg and in some cases also with anti-HBc.
Abbreviations: AASLD American Association for the Study of Liver Diseases, ASCO American Society of Clinical Oncology, CDC Centers for Disease Control and
Prevention, FDA Food and Drug Administration, IOM Institute of Medicine, NCCN National Comprehensive Cancer Network, HBsAg Hepatitis B surface antigen,
anti-HBc Antibody to hepatitis B core antibody, anti-HBs Antibody to hepatitis B surface antigen.
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reported in these studies may not reflect actual screen-
ing practices.
We previously found that only 17% of patients treated
at a US cancer center from 2004 through 2007 were
screened for HBV infection before chemotherapy [14].
The purpose of this study was to update our previous
study by determining HBV screening rates at the same
cancer center from 2004 through 2011 and to examine
the possible influence of national recommendations
published between 2004 and 2010 on HBV screening
rates over time.Methods
Data sources
We conducted a retrospective cohort study of adults
with newly diagnosed cancer who registered at The
University of Texas MD Anderson Cancer Center
between January 1, 2004, and April 30, 2011, and re-
ceived chemotherapy. This study was approved by the
MD Anderson Institutional Review Board. We merged
patient data from 4 institutional sources:1. Tumor Registry: patient demographics, including
birthplace, and cancer type (hematologic
malignancies vs. solid tumors); primary liver cancer
was excluded because of the etiologic relationship
between HBV and hepatocellular carcinoma. At MD
Anderson, patient’s race/ethnicity can be ascertained
based on self-reporting, reporting by the referring
clinic, or assignment by administrative staff. We
categorized race/ethnicity as White, Black, Hispanic,
Asian, or Other. Birthplace in a region of moderate
to high prevalence of HBV infection was considered
a risk factor for HBV infection [3].
2. Pharmacy Informatics: chemotherapy drugs
and dates administered. Chemotherapy was
classified according to American Cancer
Society classification [15]. We excluded oral
chemotherapy because we could not validate
medication dispensing dates. We excluded
patients in therapeutic clinical trials since some
clinical trials excluded patients with liver disease
or hepatitis and screening for HBV was often
dictated by the protocol and not reflective of
the investigators’ decision.
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risk factors for HBV infection (see Table 2)
anytime before the end of the screening period
(defined below).
4. Laboratory Informatics: test dates and results for
hepatitis B surface antigen (HBsAg), antibody to
hepatitis B core antibody (anti-HBc), alanine
aminotransferase, total bilirubin, and HBV DNA.
HBV screening and infection
Screening was defined as having both HBsAg and anti-
HBc tests ordered in the period from 2 months before
the first administration of chemotherapy until the sec-
ond administration of chemotherapy. MD Anderson has
no official policy recommending prechemotherapy HBV
screening. Positive findings on both HBsAg and anti-
HBc tests were considered to indicate chronic HBV
infection. Negative HBsAg test but positive anti-HBc test
were considered to indicate occult HBV infection or
convalescence after previous infection. Unfortunately,
antibody to hepatitis B surface antigen (anti-HBs) test,
which is positive in convalescence and negative in occult
disease, was ordered in only 1% of patients.
Three time periods
We used dates of the publication of national HBV rec-
ommendations to create 3 time intervals and categorized
patients in these intervals according to date of first
chemotherapy administration. We used 90 days after
publication of recommendations as cut-off dates to allow
adequate time for dissemination and potential change in
practice patterns.
 Period 1: January 1, 2004, through December 18,
2008 (includes publication of Food and Drug
Administration [FDA] letter [1] and 2007
American Association for the Study of Liver
Diseases [AASLD] [2] recommendation).
 Period 2: December 19, 2008, through September
30, 2010 (includes publication of Centers for
Disease Control and Prevention [CDC], [3] 2009
AASLD, [4] National Comprehensive Cancer
Network [NCCN], [5] Institute of Medicine [IOM]
[6] recommendations, and American Society of
Clinical Oncology [ASCO] provisional clinical
opinion [PCO] [7]).
 Period 3: October 1, 2010, through April 30, 2011
(after publication of above recommendations).
Statistical methods
We calculated screening prevalence for each time period
and tested for an increase in screening across the 3
periods using Cochran-Armitage trend tests. We com-
pared characteristics of screened and unscreened patientsusing Pearson’s chi-square tests for categorical variables
and Student’s t-test for continuous variables. We calcu-
lated screening rate per quarter and determined the rate
of change of screening prevalence per quarter by cancer
type and time period using regression analysis. Our main
outcome variable was screening using HBsAg and anti-
HBc tests. Independent variables included age, gender,
race/ethnicity, US residency, having an HBV risk factor,
cancer type, rituximab therapy, and date of first chemo-
therapy administration. We used 2 logistic regression
models to identify predictors of screening, one for patients
with solid tumors and one for patients with hematologic
malignancies. We used backward elimination to select
final models with a criterion of P > 0.05 for exclusion.
Hosmer and Lemeshow goodness-of-fit tests were used to
evaluate model fit. We determined the proportion of
positive test results among screened patients and com-
pared the rates of either a positive HBsAg test or a positive
anti-HBc test result across the 3 time periods using
Pearson’s chi-square test. We used SAS software, version
9.2 (SAS Institute, Cary, North Carolina), for statistical
analyses.
Results
During the study period, 141,877 new patients were reg-
istered at MD Anderson (Figure 1), of whom 18,688
(13.2%) received chemotherapy at MD Anderson. Over-
all, 3020 (16.2%) of the patients who received chemo-
therapy were screened for HBV infection around the
onset of chemotherapy.
The prevalence of HBV screening was approximately 4%
(581/15,031) among patients with solid tumors and nearly
67% (2439/3657) among patients with hematologic malig-
nancies. Nearly 29% (5391) of all patients had a risk factor
for HBV infection, and less than 19% of these patients
(1016) were screened. Over 10% (1977) of all patients re-
ceived rituximab, and nearly 69% of these patients (1360)
were screened. About 15% of the Asian patients and 12%
of the Black patients were screened compared to nearly
17% of the White patients (Table 2).
The prevalence of HBV screening increased slightly
across the 3 time periods, from 14.8% in period 1 to
18.2% in period 2 and 19.9% in period 3 (P < 0.001)
(Table 3). For patients with known risk factors for HBV
infection, screening prevalence increased over the 3
periods. For patients who received rituximab, screening
prevalence increased between periods 1 and 2 and then
decreased slightly in period 3. For Asian patients, screen-
ing prevalence did not change significantly over the 3
periods; for Black patients, screening prevalence increased
over the 3 periods (Table 3).
Screening was almost always performed with both
HBsAg and anti-HBc. Rates of use of the HBsAg test
alone were 0.8% in period 1, 0.4% in period 2, and 0.9%
Table 2 Characteristics of the study population by screening status
All patients Screened patients Unscreened patients P value
(N = 18,688) (N = 3020) (N = 15668)
Characteristic No. (%)a No. (%)b No. (%)b
Age, years, mean (SD) 55.0 (13.5) 52.5 (15.4) 55.5 (13.0) <0.0001
Sex <0.0001
Female 10,608 (56.8) 1305 (12.3) 9303 (87.7)
Male 8080 (43.2) 1715 (21.2) 6365 (78.8)
Race/ethnicity <0.0001
White 13,168 (70.5) 2168 (16.5) 11000 (83.5)
Hispanic 2319 (12.5) 402 (17.3) 1917 (82.7)
Black 2092 (11.2) 247 (11.8) 1845 (88.2)
Asian 508 (2.7) 76 (15.0) 432 (85.0)
Other 601 (3.2) 127 (21.1) 474 (78.9)
US residence 18,090 (96.8) 2896 (16.0) 15194 (84.0) 0.002
HBV risk factorc,d 5391 (28.8) 1016 (18.8) 4375 (81.2) <0.0001
Birthplace 1286 (6.9) 220 (17.1) 1066 (82.9)
Abnormal liver function 368 (2.0) 170 (46.2) 198 (53.8)
Hepatitis (not specified) 173 (0.9) 90 (52.0) 83 (48.0)
Hepatitis C 213 (1.1) 104 (48.8) 109 (51.2)
Other liver conditions 3821 (20.4) 610 (16.0) 3211 (84.0)
HIV 70 (0.4) 39 (55.7) 31 (44.3)
Drug abuse 39 (0.2) 15 (38.5) 24 (61.5)
Sexually transmitted disease 106 (0.6) 36 (34.0) 70 (66.0)
History of HBV infectione 78 (0.4) 20 (25.6) 58 (74.4) 0.02
Cancer type <0.0001
Solid tumorf 15,031 (80.4) 581 (3.9) 14450 (96.1)
Hematologic malignancy 3657 (19.6) 2439 (66.7) 1218 (33.3)
Chemotherapy type <0.0001
Rituximab 1977 (10.6) 1360 (68.8) 617 (31.2)
Non-rituximab 16,711 (89.4) 1660 (9.9) 15051 (90.1)
Abbreviations: HBV hepatitis B virus, HIV human immunodeficiency virus, SD standard deviation, US United States.
aThe percentages represent column percentages (denominator equal to total number of patients in the study, 18,688). For example, 56.8% (10,608/18,688) of the
patients in the study were women.
bThe percentages represent row percentages (denominator equal to total number of patients with the given characteristic). For example, 12.3% (1305/10,608) of
the females were screened for HBV infection while 87.7% (9303/10,608) were not.
cPatients born in countries with moderate to high prevalence of HBV infection according to the Centers for Disease Control and Prevention3 or at least 1 of the
following ICD-9 diagnosis codes any time before chemotherapy were considered to have a risk factor for HBV infection:
(i) abnormal liver function (codes 794.8);
(ii) hepatitis, not specific (codes 070, 070.4, 070.49, 070.5, 070.59, 070.6, 070.9, 571.4, 571.40, 571.41, 571.42, 571.49, 573.1, 573.2, 573.3, v02.6, v02.60, and v02.69);
(iii) other liver conditions (codes 571, 571.0, 571.2, 571.3, 571.5, 571.6, 571.8, 571.9, 572, 572.0, 572.2, 572.8, 573, 573.8, 573.9, 782.4, 789.1, and 794.8);
(iv) hepatitis C (codes 070.41, 070.44, 070.51, 070.54, 070.7, 070.70, 070.71, and v02.62);
(v) HIV (codes 042, 042.0, 042.1, 042.2, 043, 043.0, 043.1, 043.2, 043.3, 044.0, 044.9, 079.53, 795.71, 795.8, v08, and v65.44);
(vi) drug abuse (codes 305.9, 305.90, 305.91, 305.92, 305.93);
(vii) sexually transmitted disease (codes 054.1, 054.10, 054.19, 078, 078.10, 078.11, 078.19, 078.8, 078.88, 079.8, 079.88, 079.9, 079.98, 091, 091.0, 091.1, 091.2, 091.3,
091.4, 091.5, 091.6, 091.69, 091.7, 091.8, 091.89, 091.9, 092, 092.0, 092.9, 093, 093.8, 093.89, 093.9, 094, 094.3, 094.8, 094.89, 094.9, 095, 095.1, 095.3, 095.4, 095.5,
095.6, 095.7, 095.8, 095.9, 096, 097, 097.0, 097.1, 097.9, 099.41, 099.50, 099.51, 099.52, 099.53, 099.54, 099.55, 099.56, 099.59, 483.1, v02.7, v73.8).
dSum of patient numbers in the individual risk factor categories exceeds total number of patients with risk factors (n = 5391) since some patients had more than 1
HBV risk factor.
eWe considered patients to have a history of HBV infection if they had an ICD-9 code for HBV infection (0.70.22, 0.70.23, 0.70.30, 0.70.32, 0.70.33, 0.70.44, 0.70.51,
0.70.54, 0.70.70, v02.61, v02.62) either 1) before HBV screening test among patients who were screened, or 2) before the second chemotherapy administration
among patients who did not have HBV screening.
fExcludes primary liver cancer.
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141,877 New patients with cancer,
without prior history of cancer
21,396 New patients had any type of 
chemotherapy
18,688 New patients with cancer 
other than primary liver cancer who 
had parenteral chemotherapy 
120,481 excluded for lack of  
chemotherapy
2708 excluded for:
Investigational chemotherapy (n = 1406) 
Nonparenteral routes of chemotherapy (n 
= 1102)
Unknown route of administration of 
chemotherapy (n = 14)
Primary liver cancer (n = 186) 
Figure 1 Study patient population. Flow diagram for study patients showing the exclusion of patients who did not have chemotherapy, had
investigational chemotherapy, or non-parenteral routes of chemotherapy. Patients with primary liver cancer were also excluded.
Table 3 Rates of HBV screeninga by screening period
Characteristic Period 1b Period 2c Period 3d P valuee
All patients Screened patients All patients Screened patients All patients Screened patients
(N = 11,833) (N = 1754) (N = 5703) (N = 1037) (N = 1152) (N = 229)
Age, years, mean (SD) 54.8 (13.6) 51.6 (15.6) 55.1 (13.4) 53.1 (15.2) 56.4 (13.1) 56.1 (14.7) 0.0001
Sex, no. (%)
Female 6702 731 (10.9) 3263 464 (14.2) 14.22 643 110 (17.1) 17.11 <0.0001
Male 5131 1023 (20.0) 19.94 2440 573 (23.5) 23.48 509 119 (23.4) 23.38 0.0003
Race/ethnicity, no. (%)
White 8464 1269 (15.0) 3895 738 (19.0) 809 161 (19.9) <0.0001
Hispanic 1441 218 (15.1) 747 152 (20.4) 131 32 (24.0) <0.0001
Black 1301 143 (11.0) 654 83 (12.7) 137 21 (15.3) 0.04
Asian 311 45 (14.5) 158 23 (14.6) 39 8 (19.4) 0.23
Other 316 79 (25.0) 249 41(16.5) 36 7 (20.5) 0.02
US residence, no. (%) 11,480 1675 (14.6) 5499 997 (18.1) 1111 224 (20.0) <0.0001
HBV risk factor, no. (%) 3412 572 (16.8) 1668 356 (21.3) 311 88 (28.3) <0.0001
Cancer type, no. (%) <0.0001
Solid tumorf 9521 326 (3.4) 4602 208 (4.5) 908 47 (5.2) <0.0001
Hematologic malignancy 2312 1428 (61.8) 1101 829 (75.3) 244 182 (74.6) <0.0001
Chemotherapy
Type, n (%)
Rituximab 1244 785 (63.1) 606 481 (79.4) 127 94 (74.0) <0.0001
Non-rituximab 10,589 969 (9.4) 5097 556 (10.9) 1025 135 (13.2) <0.0001
Abbreviations: HBV hepatitis B virus, SD standard deviation, US United States.
aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
bFirst chemotherapy administration from 1/1/04 through 12/18/2008.
cFirst chemotherapy administration from 12/19/2008 through 9/30/2010.
dFirst chemotherapy administration from 10/1/2010 through 4/30/11.
eCochran-Armitage trend test compares screened patients vs. unscreened patients, over the 3 time periods.
fExcludes primary liver cancer.
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tients, 252 (8.3%) had a positive result for either HBsAg
or anti-HBc test. Specifically, 31 (1.0%) had positive
results on both HBsAg and anti-HBc tests, 218 (7.2%)
had a negative HBsAg test and a positive anti-HBc test,
and 3 (0.1%) had a positive HBsAg but negative anti-
HBc. Assuming that unscreened patients had negative
tests, the proportions of patients with a positive result
on either HBsAg or anti-HBc testing among all patients
who received chemotherapy in periods 1, 2, and 3 were
1.4% (169/11,833), 1.5% (84/5703), and 1.7% (19/1152),
respectively (P < 0.0001).
Solid tumors
Among patients with solid tumors, screening rates for pe-
riods 1, 2, and 3, respectively, were as follows: breast: 2.1%,
2.2%, 5.8% (P = 0.01); lung: 1.1%, 2.9%, 2.9% (P = 0.009);
colon: 3.5%, 4.6%, 3.4% (P = 0.30); and prostate: 2.8%, 2.9%,
2.8% (P = 0.37). The odds of HBV screening were increased
by 30% and 70% for patients who had chemotherapy in pe-
riods 2 and 3, respectively, compared to period 1 (Table 4).
Other significant predictors of higher rate of HBV screen-
ing were younger age, male gender, US residence, having at
least 1 HBV risk factor, and planned rituximab therapy.
HBV screening was performed in 64.4% of patients with
and in 3.2% without rituximab in their chemotherapy
regimen.
Hematologic malignancies
Among patients with hematologic malignancies, the
screening rate increased during period 1 by 1% per quarter
and then stabilized for periods 2 and 3 (Figure 2). This pat-
tern was seen in lymphoma patients (63.5%, 81.3%, 81.3%
for periods 1, 2, and 3, respectively; P ≤ 0.001) and acute
leukemia patients (75.2%, 88.9%, 89.1% for periods 1, 2, and
3, respectively; P ≤ 0.001). The odds of screening were
nearly twice as high for patients who had chemotherapy in
period 2 as for patients who had chemotherapy in period 1
(Table 4). No incremental effect was observed after publica-
tion of national recommendations. Other significant predic-
tors of screening were younger age, having at least 1 HBV
risk factor, and planned rituximab therapy. HBV screening
was performed in 69.2% of patients with and 64.2% of pa-
tients without rituximab in their chemotherapy regimen.
Black race was associated with a lower screening rate.
Discussion
We found that the HBV screening prevalence among
new patients receiving chemotherapy at a large US can-
cer center over the period 2004–2011 was only 16.2%.
Of particular concern, the prevalence of HBV screening
was low (<19%) even for patients with known HBV risk
factors. Over 66% of patients with hematologic malig-
nancies but less than 4% of those with solid tumors werescreened. Predictors of HBV screening included having
an HBV risk factor and planned rituximab therapy.
Interestingly, race/ethnicity was associated with the likeli-
hood of HBV screening for patients with hematologic
malignancies but not with solid tumors. Importantly, HBV
screening prevalence increased over time and higher rates
were sustained after publication of national HBV screen-
ing recommendations. In this study of provider-driven
screening, 8.3% of screened patients had a positive HBsAg
or anti-HBc test result. The proportion of patients who
tested positive for HBV infection increased by over 20%
from period 1 to period 3, suggesting that increased
screening may lead to increased identification of patients
with HBV infection.
The finding that most patients with hematologic ma-
lignancies were screened for HBV infection whereas
most patients with known HBV risk factors were not,
together with the finding that most patients who received
rituximab, a known risk factor for reactivation, were
screened, suggests that oncologists are more aware of the
risk factors for HBV reactivation than they are of the risk
factors for HBV infection. This may have reflected the
effect of the FDA letters, package inserts, and recommen-
dations as well as publications in the oncology literature
about HBV reactivation associated with rituximab treat-
ment. These data indicate that future educational efforts
on risk factors for HBV infection for oncology providers
might increase HBV screening.
For patients with hematologic malignancies, the preva-
lence of HBV screening increased dramatically during
period 1, which included the FDA letter. This increase
may be related to the high risk (nearly 50%) of reactivation
[16] and frequent reports of reactivation among patients
with hematologic malignancies [17-19] and to the fre-
quent reports of reactivation among patients receiving
rituximab [20-24]. The further increase in screening
prevalence during periods 2 and 3 was likely due to the
emphasis in national recommendations on the risk of
HBV reactivation in these patients.
For patients with solid tumors, odds of screening
increased over all 3 time periods; however, the vast
majority (96%) of patients were not screened. The low
rate of HBV screening among patients with solid
tumors is concerning because of previous reports of
reactivation and related delays in chemotherapy and
increases in mortality in patients with breast cancer
[25-27], glioblastoma [28], germ cell tumors [27], and
cancers of the lung, colon, and stomach [27,29-31].
Indeed, the risk of reactivation among patients with
solid tumors is estimated to be approximately 15%
[27]; however, these data were derived in an HBV-
endemic area. Therefore, studies are needed to define risks
and to determine predictors of reactivation for US patients
with solid tumors.
Table 4 Predictors of HBV screeninga by cancer type









(N=2439) (66.7%) OR (95% CI) P value (95% CI) P value (N=581) (3.9%) OR (95% CI) P value OR (95% CI) P value
Age, years, mean (SD) 52.5 (15.5) 0.99 (0.99–1.0) 0.005 0.99 (0.98–0.99) 0.0001 52.4 (15.0) 0.98 (0.98–0.99) <0.0001 0.98 (0.97–0.98) <0.0001
Sex, no. (%)
Male 1418/2133 (66.5) Ref. - - - 297/5947 (5.0) Ref. - Ref. -
Female 1021/1524 (67.0) 1.0 (0.89–1.2) 0.74 - - 284/9084 (3.1) 0.61 (0.52–0.73) <0.0001 0.58 (0.49–0.70) <0.0001
Race/ethnicity, no. (%)
White 1776/2645 (67.2) Ref. - Ref. - 392/10,523 (3.7) Ref. - - -
Hispanic 324/486 (66.7) 0.98 (0.80–1.2) 0.84 0.92 (0.75–1.1) 0.45 78/1833 (4.3) 1.1 (0.90–1.5) 0.27 - -
Black 196/333 (58.9) 0.70 (0.56–0.88) 0.003 0.69 (0.55–0.88) 0.002 51/1759 (2.9) 0.77 (0.57–1.0) 0.09 - -
Asian 41/50 (82.0) 2.2 (1.1–4.6) 0.03 2.0 (0.98–4.3) 0.06 35/458 (7.6) 2.1 (1.5–3.1) <0.0001 - -
Other 102/143 (71.3) 1.2 (0.8–1.8) 0.23 1.0 (0.72–1.6) 0.79 25/458 (5.5) 1.5 (0.98–2.3) 0.06 - -
Residence, no. (%)
US 2332/3510 (66.4) Ref. - - - 564/14,580 (3.9) Ref. - Ref. -
Outside US 107/147(72.8) 1.4 (0.93–2.0) 0.11 - - 17/451 (3.8) 0.97 (0.59–1.6) 0.92 0.51 (0.30–0.90) 0.02
HBV risk factor, no. (%)
No 1683/2603 (64.7) Ref. - Ref. - 321/10,694 (3.0) Ref. - Ref.
Yes 756/1054 (71.7) 1.4 (1.2–1.6) <0.0001 1.3 (1.1–1.5) 0.001 260/4337 (6.0) 2.1 (1.7–2.4) <0.0001 2.5 (2.1–3.0) <0.0001
Chemotherapy type, no. (%)
Non-rituximab 1191/1854 (64.2) Ref. - Ref. - 469/14,857 (3.2) Ref. - Ref. -
Rituximab 1248/1803 (69.2) 1.2 (1.1–1.4) 0.001 1.3 (1.2–1.5) <0.0001 112/174 (64.4) 55.4 (40.1–76.6) <0.0001 62.0 (44.1–87.0) <0.0001
Timing of first chemotherapyc
Period 1 1428/2312 (61.8) Ref. - Ref. - 326/9521 (3.4) Ref. - Ref. -
Period 2 829/1101 (75.3) 1.9 (1.6–2.2) <0.0001 2.0 (1.6–2.3) <0.0001 208/4602 (4.5) 1.3 (1.1–1.6) 0.001 1.3 (1.1–1.6) 0.003
Period 3 182/244 (74.6) 1.8 (1.4–2.4) <0.0001 1.9 (1.4–2.6) <0.0001 47/908 (5.2) 1.5 (1.1–2. 1) 0.007 1.7 (1.2–2.3) 0.003
Abbreviations: HBV hepatitis B virus, OR odds ratio, CI confidence interval, Ref., reference.
aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
bExcludes patients with primary liver cancer.



















Figure 2 Trends in HBV Screening at MD Anderson Cancer, 2004–2011, in relation to publication of recommendations. HBV screening
prevalence is shown for patients with hematologic malignancies (blue line) and solid tumors (green line). Data points indicate average screening
prevalence per quarter (Q) of each year. Q1, Jan 1-Mar 31; Q2, Apr 1-Jun 30; Q3, Jul 1-Sept 30; Q4, Oct 1-Dec 31. Numbers at top of figure refer
to publication of national recommendations and associated reference number, as follows: 1, US Food and Drug Administration; 2, American
Association for the Study of Liver Diseases (2007); 3, Centers for Disease Control and Prevention; 4, American Association for the Study of Liver
Diseases (2009); 5, National Comprehensive Cancer Network; 6, Institute of Medicine; and 7, American Society of Clinical Oncology.
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for prechemotherapy HBV screening in patients with
high risk of HBV infection. Although the overall screen-
ing prevalence among patients with HBV risk factors
was low, the prevalence increased over time, and having
an HBV risk factor predicted screening. However, since
previous studies have shown that screening based on
risk factors alone would miss up to 45% to 65% of
patients who actually had HBV infection, [32,33] future
research is warranted to better understand the efficacy
of risk-based screening.
Our study’s screening rate is lower than that in pre-
vious studies, which have described rates of adherence
to cancer-related guidelines ranging from 27% to 97%,
[34-41] although it is possible that our screening rates
may have underestimated the actual rate since we could
not verify HBV screening performed before registration
at MD Anderson. Reasons for noncompliance with HBV
screening guidelines may have included patient char-
acteristics such as age [34,38] and stage of disease
[34], physician attitudes towards guidelines [42], and
education about guidelines [43]. One study [44] found
that physicians’ lack of awareness of and lack of
agreement with guidelines were potential barriers to
adherence. A previous study by In et al. [45] reported
a higher variation in surgical cancer care when guide-
lines were based on low levels of evidence or expert
opinion. Future research providing high levels of evi-
dence will be necessary to improve adherence to HBV
screening.We found that rituximab was a predictor of screening
for all patients, especially those with solid tumors. Rituxi-
mab is a monoclonal antibody against CD20+ that causes
severe B-cell depletion [46,47] and facilitates uncontrolled
replication of HBV. However, besides rituximab, many
other chemotherapy drugs [25-28,48-54] have been associ-
ated with HBV reactivation. Future studies focusing on
mechanisms by which certain chemotherapy drugs may
cause reactivation will help shape future evidence-based
screening strategies.
Interestingly, whereas race/ethnicity did not predict
HBV screening among patients with solid tumors, among
patients with hematologic malignancies, Black patients
had lower odds of screening than White patients. This is
concerning because previous population-based studies
have shown that the prevalence of HBV infection (current
and past) is higher among Black than White adults (9.6%
vs. 2.3%, P < 0.001) [55]. Perhaps physicians are unaware
of the higher HBV risk in Black patients. We were
surprised that Asian race did not predict HBV screening
even though the prevalence of chronic HBV infection in
this group may be as high as 20% [55-57]. Failure to
screen Asian patients may have reflected lack of awareness
by physicians of HBV risk factors [58,59]. In addition, we
were surprised that patients with solid tumors who
resided outside the US had lower odds of HBV screening,
although it is possible that they were screened in their
home countries.
We found substantial numbers of patients who had a
negative HBsAg test result but a positive anti-HBc test
Hwang et al. BMC Cancer 2013, 13:534 Page 9 of 11
http://www.biomedcentral.com/1471-2407/13/534result. Such patients may have occult HBV infection, as
underscored by the high risk (78%) of HBV transmission
in recipients transplanted with livers from donors with
isolated anti-HBc positivity as compared to donors who
were anti-HBc negative (0.05%) [60]. It is possible that
isolated anti-HBc may represent false-positive test result
among populations with a low prevalence of HBV infec-
tion. However, reactivation has been reported in patients
who are HBsAg negative but anti-HBc positive during
chemotherapy particularly if the regimen includes rituxi-
mab [21,24,61]. The ASCO PCO [7] recommends anti-
HBc testing in some populations—e.g., patients with
hematologic malignancies—since the risk of reactivation
has been reported to be 10% among patients with hema-
tologic malignancies with isolated anti-HBc [62]. The
CDC recommends HBV screening using 3 HBV serology
tests. We found that anti-HBs was rarely tested during
our study period.
The strengths of our study include the large and het-
erogeneous patient population and the focus on actual
rather than recalled HBV screening practice. Previous
survey studies estimated 38%-80% of physicians screen
patients before chemotherapy [11-13]; however, those
results may inaccurately describe screening patterns
since surveys record self-reporting of screening practice
and not actual screening of individual patients. Our
examination of physicians’ actual screening behavior at
the level of individual patients avoided recall bias or sub-
conscious attempts to report what should be done rather
than what was actually done.
The main limitation of our study is its retrospective de-
sign and use of administrative databases, which prevented
us from fully assessing HBV history and HBV risk factors.
Patients may have received chemotherapy before their first
chemotherapy administration at MD Anderson. Also, we
excluded oral chemotherapy because we could not accur-
ately access dispensing records outside of MD Anderson,
but some oral chemotherapy could cause HBV. Patients’
race/ethnicity was self-described or assigned by referring
clinics and may be incorrect. Another limitation is that we
were not able to accurately determine prevalence of reacti-
vation since not all patients who received chemotherapy
were screened for HBV infection. This single-institution
experience may not be generalizable to other settings, and
our data cannot be generalized to patients who receive
care in clinical trials as such patients were excluded. We
did not explore socioeconomic factors such as income
and educational level because this information is not part
of our institutional Tumor Registry database. Most of our
patients at MD Anderson have health insurance, and these
plans are expected to pay for HBV screening tests. Finally,
the last time period in our study was relatively short, limit-
ing our ability to assess the full impact of the national rec-
ommendations. Nevertheless, our study provides valuabledata from a large US academic cancer center with no
changes in institutional policies regarding HBV screening
during the study period.
Conclusions
In conclusion, we found that the prevalence of HBV
screening before chemotherapy among new patients re-
ceiving chemotherapy at a large US cancer center during
2004–2011 was only 16.2% overall but increased over
time. The vast majority of patients with solid tumors, even
those with risk factors for HBV infection, remained
unscreened. Future research is needed to explore risks
and predictors of reactivation with chemotherapy for US
patients to develop evidence-based screening guidelines.
Once these are available, educational efforts should be
developed to increase oncology medical providers’ aware-
ness of the importance of HBV screening and prophylaxis
to prevent reactivation due to chemotherapy.
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